文献速递MDS 与骨髓增殖性肿瘤

芦可替尼联合地西他滨治疗加速期及急变期骨髓增殖性肿瘤的安全性与疗效

Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms.
PubMed 文献 · Blood Adv · 2018-01-01

这项多中心1期研究纳入21例加速期或急变期骨髓增殖性肿瘤(MPN-AP/BP)患者,给予地西他滨(20 mg/m2/天,共5天)联合剂量递增芦可替尼(10、15、25或50 mg每日两次),28天为一周期。未达到最大耐受剂量。可评估患者总缓解率为9/17(53%),意向性分析为9/21(42.9%),中位总生存7.9个月(95%CI 4.1-未达到)。联合方案总体耐受良好,显示潜在临床活性;一项2期试验正在进行中。

要点

  • 多中心1期研究纳入21例MPN-AP/BP患者,芦可替尼剂量递增联合地西他滨未达到最大耐受剂量。
  • 可评估患者总缓解率9/17(53%),意向性分析9/21(42.9%),中位总生存7.9个月(95%CI 4.1-未达到)。
  • 停药最常见原因为毒性/不良事件(37%)和疾病进展(21%),14例患者在治疗或随访期间死亡。

核心结论

  • 地西他滨联合芦可替尼在MPN-AP/BP患者中总体耐受良好,并显示出可能具有前景的临床活性。
  • 一项评估该联合方案疗效的2期试验正在骨髓增殖性肿瘤研究联盟内进行。

研究设计与样本

  • 多中心1期研究,共纳入21例MPN-AP/BP患者。
  • 芦可替尼剂量为10、15、25或50 mg每日两次,联合地西他滨20 mg/m2/天共5天,28天为一周期。

主要发现

  • 未达到最大耐受剂量。
  • 停药最常见原因为毒性/不良事件(37%)和疾病进展(21%)。
  • 14例患者在治疗期间或随访期间死亡。
  • 中位总生存为7.9个月(95%CI 4.1-未达到)。
  • 可评估患者总缓解率(按方案定义:完全缓解伴血细胞计数不完全恢复+部分缓解)为9/17(53%),意向性分析为9/21(42.9%)。

关键数值与推荐

  • 总缓解率按方案定义(完全缓解伴血细胞计数不完全恢复+部分缓解)为9/17(53%),意向性分析为9/21(42.9%)。
  • 中位总生存为7.9个月(95%CI 4.1-未达到)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Myeloproliferative neoplasms (MPN), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, have a propensity to evolve into accelerated and blast-phase disease (MPN-AP/BP), carrying a dismal prognosis. Conventional antileukemia therapy has limited efficacy in this setting. Thus, MPN-AP/BP is an urgent unmet clinical need. Modest responses to hypomethylating agents and single-agent ruxolitinib have been reported. More recently, combination of ruxolitinib and decitabine has demonstrated synergistic in vitro activity in human and murine systems. These observations led us to conduct a phase 1 study to explore the safety of combined decitabine and dose-escalated ruxolitinib in patients with MPN-AP/BP. A total of 21 patients were accrued to this multicenter study. Ruxolitinib was administered at doses of 10, 15, 25, or 50 mg twice daily in combination with decitabine (20 mg/m2 per day for 5 days) in 28-day cycles. The maximum tolerated dose was not reached. The most common reasons for study discontinuation were toxicity/adverse events (37%) and disease progression (21%). Fourteen patients died during study treatment period or follow-up. The median overall survival for patients on study was 7.9 months (95% confidence interval, 4.1-not reached). Among evaluable patients, the overall response rate by protocol-defined criteria (complete remission with incomplete count recovery + partial remission) was 9/17 (53%) and by intention-to-treat analysis was 9/21 (42.9%). The combination of decitabine and ruxolitinib was generally well tolerated by patients with MPN-AP/BP and demonstrates potentially promising clinical activity. A phase 2 trial evaluating the efficacy of this combination regimen is ongoing within the Myeloproliferative Disorder Research Consortium.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Rampal RK, Mascarenhas JO, Kosiorek HE, et al. Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms. Blood Adv. 2018. PMID: 30563881. doi:10.1182/bloodadvances.2018019661

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。